HRP20160953T1 - Vodeni farmaceutski sastavi koji sadrže komplekse borat-poliol - Google Patents

Vodeni farmaceutski sastavi koji sadrže komplekse borat-poliol

Info

Publication number
HRP20160953T1
HRP20160953T1 HRP20160953TT HRP20160953T HRP20160953T1 HR P20160953 T1 HRP20160953 T1 HR P20160953T1 HR P20160953T T HRP20160953T T HR P20160953TT HR P20160953 T HRP20160953 T HR P20160953T HR P20160953 T1 HRP20160953 T1 HR P20160953T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical compositions
compositions containing
aqueous pharmaceutical
containing borate
polyol complexes
Prior art date
Application number
HRP20160953TT
Other languages
English (en)
Inventor
Bhagwati P. Kabra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42364357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160953(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20160953T1 publication Critical patent/HRP20160953T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20160953TT 2009-06-19 2016-07-27 Vodeni farmaceutski sastavi koji sadrže komplekse borat-poliol HRP20160953T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21847209P 2009-06-19 2009-06-19
EP14150805.1A EP2722035B1 (en) 2009-06-19 2010-06-17 Aqueous pharmaceutical compositions containing borate-polyol complexes

Publications (1)

Publication Number Publication Date
HRP20160953T1 true HRP20160953T1 (hr) 2016-10-07

Family

ID=42364357

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160953TT HRP20160953T1 (hr) 2009-06-19 2016-07-27 Vodeni farmaceutski sastavi koji sadrže komplekse borat-poliol
HRP20200979TT HRP20200979T1 (hr) 2009-06-19 2020-06-19 Vodeni farmaceutski pripravci koji sadrže komplekse borat-poliol

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20200979TT HRP20200979T1 (hr) 2009-06-19 2020-06-19 Vodeni farmaceutski pripravci koji sadrže komplekse borat-poliol

Country Status (27)

Country Link
US (3) US9044484B2 (hr)
EP (4) EP2442790B1 (hr)
JP (3) JP6017956B2 (hr)
KR (1) KR101738502B1 (hr)
CN (2) CN104707145A (hr)
AR (2) AR077126A1 (hr)
AU (1) AU2010262898B2 (hr)
BR (1) BRPI1015996B8 (hr)
CA (1) CA2763778C (hr)
CL (1) CL2010000634A1 (hr)
CY (2) CY1117835T1 (hr)
DK (3) DK2722035T3 (hr)
ES (3) ES2584858T3 (hr)
HK (2) HK1194007A1 (hr)
HR (2) HRP20160953T1 (hr)
HU (2) HUE049477T2 (hr)
LT (1) LT3045164T (hr)
MX (1) MX2011013107A (hr)
PL (3) PL3045164T3 (hr)
PT (3) PT2722035T (hr)
RU (1) RU2563125C2 (hr)
SI (3) SI2442790T1 (hr)
SM (1) SMT201600249B (hr)
TW (1) TWI489997B (hr)
UY (1) UY32709A (hr)
WO (1) WO2010148190A1 (hr)
ZA (1) ZA201108384B (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959500A (zh) * 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
BR112013018025A2 (pt) * 2011-01-18 2020-10-27 Senju Pharmaceutical Co., Ltd composição de bromfenac líquida aquosa método para reforçar a eficácia conservante de uma solução aquosa
RU2601115C2 (ru) 2011-04-22 2016-10-27 Алькон Рисерч, Лтд. Офтальмологическая композиция с повышающей вязкость системой, содержащей два различных средства повышения вязкости
WO2012145460A2 (en) 2011-04-22 2012-10-26 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CA2899342C (en) 2013-02-01 2021-09-21 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
US9795560B2 (en) 2013-02-01 2017-10-24 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9693563B2 (en) 2013-08-20 2017-07-04 3M Innovative Properties Company Boron-silane polyether complex
WO2017217450A1 (ja) * 2016-06-15 2017-12-21 千寿製薬株式会社 眼科用医薬製品
JP6247430B1 (ja) * 2016-06-15 2017-12-13 千寿製薬株式会社 眼科用医薬製品
CN106237337B (zh) * 2016-08-05 2019-11-08 河南中帅医药科技股份有限公司 一种液体药物制剂用防腐组合物
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP7413040B2 (ja) 2018-02-21 2024-01-15 三菱重工サーマルシステムズ株式会社 スクロール流体機械及びその設計方法
SG11202104094YA (en) 2018-10-26 2021-05-28 Ocuphire Pharma Inc Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
US20220241296A1 (en) 2019-07-23 2022-08-04 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
US20230218611A1 (en) 2020-04-29 2023-07-13 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JP3058656B2 (ja) 1990-06-18 2000-07-04 トーメー産業株式会社 コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法
RU2067456C1 (ru) 1990-12-27 1996-10-10 Эллерган, Инк. Способ дезинфекции контактных линз и композиция для дезинфекции контактных линз
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
JP2873530B2 (ja) * 1991-12-13 1999-03-24 参天製薬株式会社 ニュートン型粘性を示すカルボキシビニルポリマー含有点眼液基剤
DE69333850T3 (de) * 1992-05-06 2011-03-17 Alcon Laboratories, Inc., Fort Worth Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
CA2088927A1 (en) 1993-02-11 1994-08-12 Donald Skeffington Preservative system for vitamin e aqueous solution
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (hr) 1993-11-12 1996-04-21 Ciba Geigy Ag
WO1996003158A1 (en) 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6024954A (en) 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
BR9607808A (pt) 1995-03-20 1998-07-07 Unilever Nv Composição para limpeza da pele e processo para realçar o efeito antimicrobiano das formulações para limpeza da pele
US5683993A (en) 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
AU4428397A (en) 1996-09-20 1998-04-14 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
JPH10130156A (ja) * 1996-10-30 1998-05-19 Teika Seiyaku Kk 点眼剤組成物
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
KR100366676B1 (ko) 1996-12-13 2003-01-14 알콘 래보레이토리스, 인코퍼레이티드 안과용 조성물에 저분자량 아미노 알코올을 사용하는 방법
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
EP1348427B1 (en) 1997-07-29 2008-04-09 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
KR20030068148A (ko) 2000-11-29 2003-08-19 노파르티스 아게 수성 소독 시스템
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4844706B2 (ja) * 2001-03-12 2011-12-28 ライオン株式会社 眼科用組成物
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
TWI322828B (en) 2002-12-23 2010-04-01 Alcon Inc Use of multifunctional surface active agents to clean contact lenses
US8129431B2 (en) * 2003-01-21 2012-03-06 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
DE602004020665D1 (de) 2003-12-09 2009-05-28 Alcon Inc Verwendung von bisaminen zur verstärkung der antimn
JP2007513951A (ja) 2003-12-09 2007-05-31 アルコン、インコーポレイテッド 医薬品組成物の抗菌活性を増強する有機緩衝剤の使用
WO2005060933A1 (en) 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
CA2583622A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
WO2008002118A1 (es) 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
CN101516332B (zh) * 2006-09-21 2012-12-19 爱尔康研究有限公司 自身防腐的水性药物组合物
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
BRPI0717093A2 (pt) 2006-09-28 2013-11-26 Alcon Res Ltd Composições farmacêuticas aquosas autopreservadas
WO2008052031A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
WO2008052037A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US7705112B2 (en) 2007-04-17 2010-04-27 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
CN101959500A (zh) * 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物
US7999064B2 (en) 2009-04-23 2011-08-16 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods and associated formulations
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物

Also Published As

Publication number Publication date
PT2442790E (pt) 2014-05-12
BRPI1015996A8 (pt) 2018-01-09
BRPI1015996A2 (pt) 2016-04-26
PT2722035T (pt) 2016-08-02
PL3045164T3 (pl) 2020-10-19
PT3045164T (pt) 2020-07-14
EP2442790A1 (en) 2012-04-25
BRPI1015996B1 (pt) 2020-08-11
US20150224196A1 (en) 2015-08-13
TWI489997B (zh) 2015-07-01
HUE030435T2 (en) 2017-05-29
ES2461617T3 (es) 2014-05-20
EP2442790B1 (en) 2014-03-26
CL2010000634A1 (es) 2011-03-11
PL2442790T3 (pl) 2014-08-29
WO2010148190A1 (en) 2010-12-23
DK3045164T3 (da) 2020-07-13
ES2584858T3 (es) 2016-09-29
JP2016183198A (ja) 2016-10-20
JP2014198729A (ja) 2014-10-23
CY1123120T1 (el) 2021-10-29
KR20120028390A (ko) 2012-03-22
HUE049477T2 (hu) 2020-09-28
DK2722035T3 (en) 2016-08-01
EP3045164A1 (en) 2016-07-20
JP2012530712A (ja) 2012-12-06
PL2722035T3 (pl) 2016-11-30
SMT201600249B (it) 2016-08-31
UY32709A (es) 2010-12-31
TW201100103A (en) 2011-01-01
CY1117835T1 (el) 2017-05-17
EP2722035A1 (en) 2014-04-23
SI2722035T1 (sl) 2016-09-30
CA2763778C (en) 2016-02-02
LT3045164T (lt) 2020-07-27
AR077126A1 (es) 2011-08-03
DK2442790T3 (da) 2014-04-14
US20160324967A1 (en) 2016-11-10
HRP20200979T1 (hr) 2020-10-16
CA2763778A1 (en) 2010-12-23
AR122017A2 (es) 2022-08-03
US9044484B2 (en) 2015-06-02
EP3437634A1 (en) 2019-02-06
HK1194007A1 (zh) 2014-10-10
JP6017956B2 (ja) 2016-11-02
US20100324031A1 (en) 2010-12-23
EP2722035B1 (en) 2016-04-27
KR101738502B1 (ko) 2017-05-22
RU2563125C2 (ru) 2015-09-20
CN102802604A (zh) 2012-11-28
EP3045164B1 (en) 2020-04-15
BRPI1015996B8 (pt) 2021-05-25
RU2012101782A (ru) 2013-07-27
AU2010262898A1 (en) 2011-12-15
HK1163521A1 (en) 2012-09-14
CN102802604B (zh) 2016-02-10
MX2011013107A (es) 2012-01-20
US9421265B2 (en) 2016-08-23
SI2442790T1 (sl) 2014-05-30
CN104707145A (zh) 2015-06-17
SI3045164T1 (sl) 2020-08-31
ZA201108384B (en) 2013-01-30
ES2803648T3 (es) 2021-01-28
AU2010262898B2 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
HRP20160953T1 (hr) Vodeni farmaceutski sastavi koji sadrže komplekse borat-poliol
HK1231408A1 (zh) 藥物組合物
HK1145631A1 (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
EP2500038A4 (en) PHATMACEUTICAL COMPOSITION FOR EXTERNAL USE /
ZA201109138B (en) Pharmaceutical composition having improved solubility
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
IL201912A0 (en) Aqueous pharmaceutical composition
GB0919650D0 (en) Pharmaceutical composition
GB0902428D0 (en) Pharmaceutical methods & compositions
GB0921139D0 (en) Pharmaceutical methods & compositions
GB0910754D0 (en) Pharmaceutical agent
GB0905557D0 (en) Pharmaceutical agent
GB0905555D0 (en) Pharmaceutical agent
GB0920790D0 (en) Pharmaceutical agent
GB0905558D0 (en) Pharmaceutical agent
GB0913956D0 (en) Pharmaceutical agent